Jacobio Pharma Surpasses Expectations with Strong Mid-Year Performance

Jacobio Pharma, a leading biopharmaceutical company, has announced its mid-year performance for 2023, showcasing continuous progress in various research and development (R&D) projects. The company reported a revenue of RMB 40.3 million, with a year-on-year increase of 5.5% in R&D investment, reaching RMB 230 million.

Related article: Novo Nordisk Delivers Strong H1 Financial Performance, With Acquisition to Expand Weight Loss Market

Jacobio Pharma’s Remarkable Journey and Dedication to R&D

Jacobio Pharma’s journey has been characterized by its relentless pursuit of challenging drug targets since its inception. Dr. Wang Yinxiang, Chairman and CEO of Jacobio Pharma, emphasized that the company has positioned itself with over ten ongoing projects, leveraging its cutting-edge Induced Fit Drug (IFD) platform and iADC platform. Dr. Wang stated, “This year, we have been dedicated to exploring the therapeutic potential of Glerese, expanding its registered clinical trials from lung cancer to pancreatic cancer. These developments are promising, and with the completion of two financings this year, we have ample cash reserves to advance our R&D projects.”

Advancements in Core Clinical Projects

Jacobio Pharma’s flagship project, Glerese, has demonstrated significant progress in treating multiple types of cancer. A single-agent registration clinical trial for non-small cell lung cancer is underway in over 60 domestic hospitals, with an expected completion in September 2023. Following this, the company plans to submit a Pre-New Drug Application (Pre-NDA) by the end of 2023, with a New Drug Application (NDA) submission slated for the first half of 2024. Moreover, Glerese has been granted breakthrough therapy designation for the treatment of second-line or higher pancreatic cancer patients with KRAS G12C mutations, making it the world’s first registered clinical trial targeting this mutation.

Jacobio Pharma is pushing the boundaries of cancer treatment by exploring the SHP2 Inhibitor, JAB-3312. It is currently being tested in combination with Glerese in Phase I/IIa clinical trials in China, with over 100 patients already enrolled. Additionally, a Phase IIa dose expansion trial of JAB-3312 in combination with sotorasib is taking place in Europe and the United States, with preliminary clinical data set to be presented at the European Society for Medical Oncology (ESMO) in October 2023.

Expansion Beyond Core Projects

Jacobiopharma is not limited to its core projects. The company has extended its reach by exploring various clinical projects, including BET inhibitors (JAB-8263), Aurora kinase A inhibitors (JAB-2485), CD73 monoclonal antibodies (JAB-BX102), PAPR7 inhibitors (JAB-26766), and LIF monoclonal antibodies (JAB-BX300). These projects are progressing well in clinical trials, showing promising results in specific tumor types.

With a robust financial position and a diverse portfolio of projects, Jacobiopharma is positioned to play a pivotal role in advancing cancer treatment. The company’s dedication to innovation and commitment to groundbreaking therapies underscore its commitment to improving the lives of patients worldwide. As the battle against cancer continues, Jacobio Pharma remains at the forefront, driving advancements that offer hope to those in need.

Author

Sinead Huang